Latest News

Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45%

SEAL BEACH, Calif.–(BUSINESS WIRE)– #gu20–New study of 6,000+ Medicare patients with advanced prostate cancer shows adding PROVENGE (sipuleucel-T) to treatment reduced risk of death by 45%.

Source link

Related posts

New approach to tackling chronic inflammatory diseases


Second Leading Independent Proxy Advisory Firm Supports Medison and Recommends Change and a New Strategy at Knight Therapeutics


Medical News Today: Fibroid surgery: Everything you need to know


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World